Abstract
BackgroundThe introduction of non-VKA oral anticoagulants (NOACs) has changed the landscape of preventing thromboembolism events in many countries. However, the prescription trends of oral anticoagulant (OAC) in China are still unclear, which were evaluated in this study through data extracted and summarized from 5 major cities as representatives.MethodsThis study was designed as a time-series study which was based on pharmacy prescription data. Analysis was performed on yearly aggregated visits and expenditure. The results were also stratified by indications and specialties.ResultsA total of 189,006 prescriptions of 67 hospitals in 6 years were included in the study. The average growth rates of overall visit and expenditure of OAC were 15.8 and 57.5%, respectively. The share of warfarin decreased and NOACs had taken 92% of cost, covering 28% of patients in 2017. The more frequently used NOACs were rivaroxaban and dabigatran. The use of OAC was differed by indication and specialty.ConclusionThe use of NOACs was found increasing rapidly in both visits and cost, sharing a majority of cost with a minority of patients. Attentions should be paid on the rational use of NOACs.
Highlights
The introduction of non-Vitamin K antagonist (VKA) oral anticoagulants (NOACs) has changed the landscape of preventing thromboembolism events in many countries
Overall trends of oral anticoagulant use and expenditure The overall OAC use increased from 21,435 visits in 2012 to 44,653 visits in 2017, driven by an average growth rate of 15.8% per year (P < 0.05)
The average cost per visit of OAC kept on increasing during the study period (P < 0.05), but the average cost of warfarin remained constant (P > 0.05) and of Non-Vitamin K oral anticoagulant (NOAC) even decreased (P < 0.05)
Summary
The introduction of non-VKA oral anticoagulants (NOACs) has changed the landscape of preventing thromboembolism events in many countries. The prescription trends of oral anticoagulant (OAC) in China are still unclear, which were evaluated in this study through data extracted and summarized from 5 major cities as representatives. The introduction of non-VKA oral anticoagulants (NOACs) has changed the landscape of preventing thromboembolism events in many countries [3,4,5,6,7]. The prescription trends of oral anticoagulant in China are still unclear, which were evaluated in this study through data extracted and summarized from 5 major cities as representatives
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
